Uncategorized

Sarepta names former AbbVie R&D exec Michael Severino as next CEO

Published

on

After leaving Tessera Therapeutics earlier this month, Michael Severino will take over Sarepta Therapeutics as the biotech awaits two key regulatory decisions in Duchenne muscular dystrophy.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version